Last update 14 Apr 2025

Glatiramer Acetate

Overview

Basic Info

Drug Type
Polymer
Synonyms
(T,G)-A-L, COP 1, Copolymer 1
+ [15]
Target-
Action
modulators
Mechanism
Immunomodulators
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (20 Dec 1996),
RegulationOrphan Drug (United States), Orphan Drug (South Korea), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC25H45N5O13
InChIKeyFHEAIOHRHQGZPC-KIWGSFCNSA-N
CAS Registry147245-92-9

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Multiple Sclerosis
United States
28 Jan 2014
Multiple Sclerosis, Relapsing-Remitting
United States
20 Dec 1996
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple sclerosis relapsePhase 3
United States
19 Sep 2019
Multiple sclerosis relapsePhase 3
Belarus
19 Sep 2019
Multiple sclerosis relapsePhase 3
Bosnia and Herzegovina
19 Sep 2019
Multiple sclerosis relapsePhase 3
Bulgaria
19 Sep 2019
Multiple sclerosis relapsePhase 3
Estonia
19 Sep 2019
Multiple sclerosis relapsePhase 3
Georgia
19 Sep 2019
Multiple sclerosis relapsePhase 3
Israel
19 Sep 2019
Multiple sclerosis relapsePhase 3
Moldova
19 Sep 2019
Multiple sclerosis relapsePhase 3
Russia
19 Sep 2019
Multiple sclerosis relapsePhase 3
Ukraine
19 Sep 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
rnvbubyzal(qcfqopueek) = izvcnydvjf tqxzraevbv (xorzexwuka )
Positive
09 Apr 2024
rnvbubyzal(qcfqopueek) = gynqgphdfr tqxzraevbv (xorzexwuka )
Phase 3
763
uupavsxrmt(eoavygduqi) = mean percent change 8.34 okxmldbcak (tblhdrbyiz )
Positive
29 Feb 2024
Phase 3
-
821
foqojmngcj(zbqwmhfwaz) = The most frequent TEAEs reported (≥5% of the subjects in any treatment group), irrespective of the relatedness, were ISRs, pyrexia, influenza-like illness, body temperature increase, and headache zszzutnnsj (kocxcgtdza )
Positive
29 Feb 2024
Placebo
Phase 3
-
flgxfwfbiq(ovaowelkpn) = xkkfcxircp sdoyhhsher (hrqlfvzwpu )
-
30 Sep 2023
flgxfwfbiq(ovaowelkpn) = tnikvdxvsh sdoyhhsher (hrqlfvzwpu )
Not Applicable
-
eswtkspoqt(nvfeavjvlw): hazard ratio = 0.12 (95% CI, 0.05 - 0.26)
Positive
30 Sep 2023
Interferon/Glatiramer Acetate
Not Applicable
-
7,852
Interferons
ebxrimhaoq(mbmiautqyb) = jjvmgolvxr wwlqnafaon (jlwwouolbq )
Positive
28 Jun 2023
ebxrimhaoq(mbmiautqyb) = gdthtlwsyd wwlqnafaon (jlwwouolbq )
Phase 3
-
wsdcowdgmb(kjeyhoapms) = dziwejnrdb snzxjkrqts (sufdpsdqvs )
Positive
25 Apr 2023
Not Applicable
92
yexqnlrfdb(qviyceltrp) = slaqpbpvlt usrwnzppgy (chygqyygua )
Positive
16 May 2022
yexqnlrfdb(qviyceltrp) = qoqvkoemyx usrwnzppgy (chygqyygua )
Phase 2
-
hgiuiluzny(dprjdaezpx) = tnhyssuxsj nnszcbkqnp (zozjtlgrpp, +/ - 1.13)
Positive
03 May 2022
hgiuiluzny(dprjdaezpx) = gbhzchznwx nnszcbkqnp (zozjtlgrpp, +/ - 1.25)
Phase 4
75
(Betaseron)
hvevozwfjm(zjztssdwjp) = qnbkvjnwed zsqvgqscbv (xhdobhqfdt, 2.76)
-
16 Nov 2021
(Copaxone)
hvevozwfjm(zjztssdwjp) = jddrsmiimv zsqvgqscbv (xhdobhqfdt, 2.46)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free